Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 13

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 13
---
. Our website address is https://www.clearmindmedicine.com/.
The information contained on our website and available through our website is not incorporated by reference into and should not be considered
a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only.

<div align='center'>S-4</div>

THE OFFERING

| Common Shares offered by us                         |     | 958,222 Common Shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Common Shares outstanding prior to the offering     |     | 9,601,441 Common Shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Pre-funded warrants we are offering                 |     | We are also offering pre-funded warrants to purchase 2,984,143 Common Shares to certain purchasers whose purchase of Common Shares in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding Common Shares immediately following the closing of this offering, the opportunity to purchase pre-funded warrants, in lieu of Common Shares that would otherwise result in any such purchaser’s beneficial ownership, together with its affiliates and certain related parties, exceeding 4.99% (or, at the election of such purchaser, 9.99%) of our outstanding Common Shares immediately following the consummation of this offering. The purchase price of each pre-funded warrant is equal to the purchase price of the Common Shares in this offering minus $0.0001, the exercise price of each pre-funded warrant. Each pre-funded warrant is immediately exercisable and may be exercised at any time until it has been exercised in full. |
| Common Shares to be outstanding after this offering |     | 13,543,806 Common Shares (assuming exercise in full of the pre-funded warrants).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Offering price                                      |     | The offering price is                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 $0.20 per Common Share.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Offering price per pre-funded warrant               |     | $0.1999 per pre-funded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 warrant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

| Use of proceeds                 |     | We intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical